Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 8:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo Growth Hormone Releasing Hormone Clear all
Completed Phase 2 Interventional Results available

Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk

NCT03375788
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Obesity, Obesity, Abdominal, Liver Fat, Fatty Liver
Interventions
Tesamorelin, Identical Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Sep 29, 2026, 8:28 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers

NCT03571594
View directory record Official record
Conditions
Acromegaly
Interventions
ONO-5788, ONO-5788 Placebo, Octreotide
Drug
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Sep 29, 2026, 8:28 PM EDT
Completed Not applicable Interventional Results available

Effects of Growth Hormone Releasing Hormone in HIV

NCT01263717
View directory record Official record
Conditions
HIV, HIV Lipodystrophy
Interventions
tesamorelin, placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 29, 2017 · Synced Sep 29, 2026, 8:28 PM EDT
Completed Phase 2 Interventional Results available

The Effect of GHRH Therapy on Myocardial Structure and Function in Congestive Heart Failure

NCT00791843
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Growth hormone releasing hormone/ placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
50 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 8, 2019 · Synced Sep 29, 2026, 8:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Blood Flow Restriction With and Without Arginine on Physical Performance and Growth Hormone

NCT04079010
View directory record Official record
Conditions
Blood Flow Restriction, Growth Hormone, Strength Outcomes, Arginine
Interventions
BFR, Arginine, Placebo Pill
Procedure · Dietary Supplement
Lead sponsor
University of Mary Hardin-Baylor
Other
Eligibility
18 Years to 25 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Belton, Texas
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Sep 29, 2026, 8:28 PM EDT
Completed Phase 3 Interventional Results available

A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency

NCT04615273
View directory record Official record
Conditions
Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency
Interventions
Lonapegsomatropin, Placebo, Somatropin
Drug · Other
Lead sponsor
Ascendis Pharma Endocrinology Division A/S
Industry
Eligibility
23 Years to 80 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 29, 2026, 8:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Estradiol-Receptor Blockade in Older Men and Women

NCT02271282
View directory record Official record
Conditions
Normal Healthy Volunteers
Interventions
Toremifene, Placebo, GHRH/Ghrelin combined Injection
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 13, 2016 · Synced Sep 29, 2026, 8:28 PM EDT
Completed Not applicable Interventional Results available

Tesamorelin Effects on Liver Fat and Histology in HIV

NCT02196831
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV), Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)
Interventions
tesamorelin, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Bethesda, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 26, 2020 · Synced Sep 29, 2026, 8:28 PM EDT
Completed Phase 3 Interventional

TH9507 in Patients With HIV-Associated Lipodystrophy

NCT00123253
View directory record Official record
Conditions
HIV Infections, Lipodystrophy
Interventions
TH9507
Drug
Lead sponsor
Theratechnologies
Industry
Eligibility
18 Years to 65 Years
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
35
States / cities
Los Angeles, California • Palm Springs, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2013 · Synced Sep 29, 2026, 8:28 PM EDT
Completed Phase 3 Interventional Results available

A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency

NCT05171855
View directory record Official record
Conditions
Adult Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency
Interventions
Lonapegsomatropin
Drug
Lead sponsor
Ascendis Pharma Endocrinology Division A/S
Industry
Eligibility
23 Years to 81 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
15
States / cities
Phoenix, Arizona • Torrance, California • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 29, 2026, 8:28 PM EDT
Recruiting Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs

NCT06930625
View directory record Official record
Conditions
Acromegaly
Interventions
Debio 4126, Placebo
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
10
States / cities
Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 29, 2026, 8:28 PM EDT
Completed Phase 3 Interventional Results available

TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy

NCT00608023
View directory record Official record
Conditions
Lipodystrophy, HIV Infections
Interventions
Tesamorelin, Placebo for Tesamorelin
Drug
Lead sponsor
Theratechnologies
Industry
Eligibility
18 Years to 65 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
27
States / cities
Birmingham, Alabama • Phoenix, Arizona • Indio, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2022 · Synced Sep 29, 2026, 8:28 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Platelet Rich Plasma Injections In Young And Old Human Subjects

NCT06451120
View directory record Official record
Conditions
Osteoarthritis, Articular Cartilage, Musculoskeletal Disorders
Interventions
Platelet-Rich Plasma (PRP) Injections, Centrifuge, Control saline injection
Drug · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 29, 2026, 8:28 PM EDT
Completed Phase 1 Interventional

VRS-317 in Adult Subjects With Growth Hormone Deficiency

NCT01359488
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
VRS-317
Drug
Lead sponsor
Versartis Inc.
Industry
Eligibility
25 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2012 · Synced Sep 29, 2026, 8:28 PM EDT
Recruiting Phase 2 Interventional

Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV

NCT06554717
View directory record Official record
Conditions
HIV-1-infection, Frailty, Impaired Physical Function, Abdominal Obesity, Aging
Interventions
Tesamorelin, Placebo, Exercise
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
50 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Aurora, Colorado • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 29, 2026, 8:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Impact of Endogenous E2 on SSI and GH Rebound

NCT02026973
View directory record Official record
Conditions
Normal Healthy Volunteers
Interventions
Fulvestrant, Anastrozole, Placebo, Somatostatin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
55 Years to 80 Years · Female only
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 15, 2016 · Synced Sep 29, 2026, 8:28 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone Analogue

NCT01632592
View directory record Official record
Conditions
Abdominal Obesity
Interventions
Tesamorelin, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 23, 2014 · Synced Sep 29, 2026, 8:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment

NCT02553603
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Growth Hormone Releasing Hormone (GHRH), Placebo Growth Hormone Releasing Hormone
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
55 Years to 85 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2019 · Synced Sep 29, 2026, 8:28 PM EDT
Completed Phase 2 Interventional Results available

Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese

NCT00675506
View directory record Official record
Conditions
Abdominal Obesity, Growth Hormone Deficiency
Interventions
Growth hormone releasing hormone (GHRH) 1-44, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Sep 29, 2026, 8:28 PM EDT
Completed Phase 2 Interventional

Study of Luteinizing Hormone-Releasing Hormone Analog (LHRHa) in Pubertal Patients With Extreme Short Stature

NCT00001190
View directory record Official record
Conditions
Dwarfism, Growth Disorder
Interventions
Deslorelin
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1983 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 29, 2026, 8:28 PM EDT